Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/03009742.2016.1241298 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Rituximab is a novel chimeric monoclonal antibody that has established itself as a potent therapeutic option for autoimmune medical conditions, including systemic lupus erythematosus, owing to its mechanism of action targeting CD20 cells. Rituximab is also known to cause a spectrum of side effects including hematological abnormalities. Acute isolated thrombocytopenia following rituximab is an uncommon occurrence and, when seen, occurs in the presence of underlying hematological malignancies.
View Article and Find Full Text PDFRituximab in children with myelin oligodendrocyte glycoprotein antibody and relapsing neuroinflammatory disease.
Dev Med Child Neurol
March 2020
Division of Neurology, Department of Pediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada.
The aim of this study was to evaluate tolerability of and response to rituximab in children with myelin oligodendrocyte glycoprotein (MOG) antibody-positive relapsing neuroinflammatory disease. This was an observational study of prospectively collected data on 12 consecutive children (eight females, four males; median age at onset 10y 6mo [interquartile range {IQR} 7y 2mo-12y 5mo], median follow-up 2y 1mo [IQR 1y 7mo-2y 6mo]) with central nervous system inflammation and persistent serum MOG immunoglobulin G positivity more than 12 weeks after clinical presentation. Patients received a standardized rituximab treatment protocol.
View Article and Find Full Text PDFSpontaneous Splenic Rupture and Rituximab-Induced Acute Thrombocytopenia in a Patient with High-Risk Mantle Cell Lymphoma.
Case Rep Hematol
April 2019
Department of Haematology, Dunedin Hospital, 201 Great King Street, Dunedin 9016, New Zealand.
Mantle cell lymphoma is a relatively rare type of mature B-cell non-Hodgkin's lymphoma with an incidence of approximately 8 cases per million persons per year. In patients with mantle cell lymphoma, there are rare case reports of the potentially life-threatening consequences of splenic rupture and rituximab-induced acute thrombocytopenia (RIAT) occurring separately, but there are no reports of these occurring in the same patient. Whilst rare, they are important to be aware of as early detection may prevent fatal outcomes.
View Article and Find Full Text PDFRituximab can cause late-onset neutropenia that may result in serious life-threatening complications. The author describes the pathophysiology, incidence, and management of this adverse reaction and presents two case histories.
View Article and Find Full Text PDFLife-threatening rituximab-induced pyoderma gangrenosum successfully treated with intravenous immunoglobulin.
Scand J Rheumatol
September 2017
a Department of Medicine, Clinical Immunology Unit , Stavanger University Hospital, Stavanger , Norway.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!